BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
AJOVY (fremanezumab-vfrm) by Teva is fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (cgrp) ligand and blocks its binding to the receptor. Approved for migraine, menstrual migraine. First approved in 2018.
Drug data last refreshed 20h ago
Mechanism of Action
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
Indications (2)
Clinical Trials (1)
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Started Apr 2022
1,000 enrolled
Migraine Disorders
Worked on AJOVY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.